A study to investigate INM 750 for the treatment of epidermolysis bullosa simplex
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2015
At a glance
- Drugs INM 750 (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions; Proof of concept
- 04 Nov 2015 According to an InMed media release, this study is expected to be completed by the end of 2016.
- 08 Aug 2015 New trial record
- 06 Aug 2015 InMed anticipates commencing human proof of concept clinical studies of INM-750 in February 2016 with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US FDA.